John Butler
Infectious Disease · Sugar Land, TXNPI 1427028430
Payments from drug & device makers
Across 195 payments — averaging $46.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Viiv Healthcare Company$831
- Merck$352
- Mylan Specialty L.p.$308
- Novo Nordisk$236
- Theratechnologies Inc.$224
- plus $2K from 18 others
What the payments were for
- Consulting fees$3,14035%
- Travel & lodging$93810%
- Food & beverage$4,77953%
- Education$1402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 61 | $5,399 |
| Viiv Healthcare Company | 26 | $831 |
| Merck | 22 | $352 |
| Mylan Specialty L.p. | 6 | $308 |
| Novo Nordisk | 2 | $236 |
| Theratechnologies Inc. | 3 | $224 |
| AbbVie(2 entities) | 19 | $222 |
| Paratek Pharmaceuticals, Inc. | 11 | $189 |
| Insmed, Inc. | 7 | $168 |
| Madrigal Pharmaceuticals | 1 | $147 |
| EMD Serono, Inc. | 8 | $147 |
| Janssen Products, LP | 1 | $124 |
| Amgen | 1 | $122 |
| Astellas Pharma US Inc | 5 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Tetraphase Pharmaceuticals, Inc. | 5 | $93 |
| Melinta Therapeutics, LLC | 4 | $59 |
| Cumberland Pharmaceuticals, Inc. | 3 | $45 |
| Pfizer | 3 | $39 |
| Mayne Pharma Commercial LLC | 2 | $24 |
| Dynavax Technologies Corporation | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,998 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 291 | $1,148,842 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 109 | $390,959 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 56 | $258,577 |
| TivicayDolutegravir Sodium | 96 | $216,306 |
| PrezcobixDarunavir/Cobicistat | 69 | $167,263 |
| CabenuvaCabotegravir/Rilpivirine | 24 | $157,337 |
| DescovyEmtricitabine/Tenofov Alafenam | 41 | $92,448 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $75,252 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $45,051 |
| PifeltroDoravirine | 25 | $41,878 |
| MounjaroTirzepatide | 27 | $36,379 |
| Darunavir | 16 | $17,655 |
| FarxigaDapagliflozin Propanediol | 11 | $8,572 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $6,786 |
| Ritonavir | 23 | $1,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $5,399 | $1,286,340344 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva | $831 | $764,603229 claims |
| Janssen Products, LPSymtuza | $124 | $258,57756 claims |
| Johnson & JohnsonPrezcobix | $13 | $167,26369 claims |
| MerckPifeltro | $352 | $41,87825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Sugar Land
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Cheryl McDonaldFort Worth$3.1M
- Ogechika AlozieEl Paso$2.5M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
- Kevin GrimesHouston$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.